A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Exclusion Criteria

• •Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders.
• •Prior or current use of depigmentation treatments (eg, monobenzone).
• •Active or recurrent genital warts or herpes.
• •Male participants with partners with known current/active cervical intraepithelial neoplasia or anal intraepithelial neoplasia.
• •An active sexually transmitted disease, sexually transmitted infection, or other skin disorder affecting the genital area (eg, scabies, fungal infection, molluscum).
• •Had ≥ 3 laser hair removal treatments in an area to be treated for vitiligo.
• •Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study or interpretation of study data.
• •Clinical laboratory test results outside of protocol defined ranges
• •Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.